This website provides information about laboratory diagnostic services. The analyses presented are not a therapy and do not replace medical diagnosis and treatment. Medical decisions are made exclusively by your attending physician.

Discover the highlights of our scientific tumor lectures/ tumor training lectures or tumor lectures congress from the successful Cancer Diagnostics Medical Congress in May 2025, ! The scientific cancer lectures / scientific oncology lectures of our international experts have set new standards in tumor medicine.

Our tumor lectures congress covered the latest research findings and innovative diagnostic procedures. The scientific oncology lectures showed impressive progress in personalized tumour medicine. This cancer lectures congress documentation summarizes the most important findings.

The tumor training lectures at our congress inspired over 500 oncology professionals. Each expert lecture on tumor diagnostics brought new insights for daily practice. Our scientific tumor presentations and cancer education lectures offer you valuable content to read up on .

Review of the Therapist Congress 2026 of iQMedix GmbH

Advanced training at the highest level

New insights, inspiring encounters and impulses for your practice

Our Therapeutics Congress took place on March 21, 2026 – and it was an extraordinary day. With over 70 participants, we doubled the number of visitors compared to 2025 – a strong signal of the growing importance of molecular oncological diagnostics and personalized therapy.

Renowned experts from science, clinics and practice gave seven presentations on the latest findings and developments in modern oncology.

The topics of the day

The path of your sample through our laboratory

Dr. Daniel Heylmann, Senior Scientist at iQMedix, took the participants behind the scenes: How does a sample pass through our laboratory – from arrival to findings? A transparent insight into processes that form the basis of every personalized therapy decision.

Better vitamin D3 uptake for cancer therapy

Dr. Alexander Michalzik, founder of Biotikon and head of a naturopathic practice for integrative homeopathy, showed how the bioavailability of vitamin D3 can be optimized – and the specific significance of this for cancer patients.

Newer oncological therapies

Dr. Reiner Hubert Steffan, Managing Director and Chief Scientist at iQMedix, gave a well-founded overview of current developments in oncology – with a focus on approaches that are becoming increasingly important in modern oncology.

DNA repair in senescence and cancer therapy

Prof. Dr. Bernd Kaina from the Institute of Toxicology at the Mainz University Medical Center devoted himself to a fascinating field of research: What role do DNA repair mechanisms play in the development and treatment of cancer – and how does cellular senescence influence this process?

Minimally invasive therapies in modern oncology - a well-kept secret

Prof. Dr. med. Attila Kovács, Chief Physician for Diagnostic and Interventional Radiology at the Wege Clinic in Bonn, presented modern minimally invasive procedures in oncology – methods which, despite their effectiveness, still receive too little attention in public discourse.

Nutrition as the foundation of cancer therapy

Prof. Dr. Roland Hennes, Medical Director at SUN AG, made it clear that nutrition is not a marginal issue, but a central component of any oncological therapy. His presentation showed how nutritional strategies are increasingly being discussed as an integral part of oncological care.

Vitamins for cancer: benefit or harm?

Dr. Reinhard Becker, MD, Managing Director of iQMedix, concluded the day of lectures with one of the most discussed questions in integrative oncology – and provided a differentiated, evidence-based answer as to when vitamins help and when caution is advised.

Delve deeper into the topics

We will soon be providing further content and information on selected presentations here on our website. Please check back regularly – we will be adding to the articles on an ongoing basis.

We look forward to continuing our discussions with you – and to the next congress in 2027.

Tumor Lectures Congress – Innovative Research Results

The tumor lectures congress of our event presented groundbreaking developments in molecular tumor diagnostics. Our krebs vorträge kongress highlighted new biomarkers and their clinical application. The tumor lectures congress impressively demonstrated the future of personalized tumor medicine.

Scientific oncology lectures – International expertise

The scientific oncology lectures were given by world-renowned tumor researchers and clinicians. Our scientific tumor presentations covered all relevant areas of modern oncology. The scientific oncology lectures offered participants unique insights into current tumor research projects.

Tumor Training Lectures – Practice-relevant training

The tumor training lectures successfully combined scientific findings with practical application. Our cancer training lectures showed directly implementable improvements for patient care. With tumor fortbildung vorträge, participants received valuable CME points and practical knowledge.

Expert lecture on tumor diagnostics – Groundbreaking presentations

Each expertenvortrag tumordiagnostik presentation was given by leading specialists in international tumor medicine. The expertenvortrag krebsdiagnostik presentations covered cutting-edge technologies and methods. These expertenvortrag tumordiagnostik sessions set new standards for cancer diagnostics education.

Thanks for the feedback

On behalf of the entire team and all of this year's speakers, we would like to thank you for your valuable feedback

I attended the iQMedix Therapy Congress on 21.03.2026 and it was a very valuable event. The presentations were not only very informative, but also excellently put together. You could clearly feel how much care and commitment went into the selection of topics and speakers. I particularly liked the successful mix of current scientific findings and practical impulses for everyday practice. I was able to take a lot of the content directly with me and reflect on it - that's what makes a really good congress for me. The pleasant atmosphere and great organization also rounded off the day. There was plenty of room for exchange, new contacts and inspiring discussions. A big thank you to the entire team for this successful event and I would love to come back!

Rated 5 out of 5

So informative, friendly and competent. Thank you for so much knowledge sharing and scientific networking!

Rated 5 out of 5

Conclusion

A congress that moves

The iQMedix GmbH Therapists’ Congress 2026 once again demonstrated the power of direct exchange between experts. Well-founded lectures, lively discussions and pioneering approaches in tumor diagnostics and therapy enriched the participants and provided new impetus for daily practice. Recognized as certified further training, the participating doctors were also able to acquire 10 CME points. The consistently positive feedback confirms this: This event is an essential date in the calendar of medical professionals. We look forward to welcoming you again in 2027 – make a note of our next congress now.

Ready for personalized diagnostics?

Personalized diagnostics makes it possible to comprehensively analyse relevant tumour activities regardless of the type of cancer. The knowledge gained forms the basis for individual complementary therapy considerations – tailored to the respective stage of the disease and oriented towards the gentlest possible treatment path.

tumor diagnostics cancer

iPREVENT

The blood test for early detection or monitoring of cancer

cancer diagnostics

iSELECT

Comprehensive personalized tumor diagnostics for complementary therapeutics

Runs a full panel of 34 gene expressions+ gene expressions and analyzes which natural substances or off-label drugs will dampen the over-expressed genes.

Liquid Biopsy for cancer

iCOMPLETE

The blood test for comprehensive analysis of your tumor activity.

Runs a full panel of 85+ gene expressions and analyzes which approved drugs, including chemotherapeutics, targeted drugs and immunotherapies, as well as natural compounds or off-label drugs, will dampen the overexpressed genes.

Your knowledge advantage starts here:

Contact us at any time

CONTACT FORM DOCTOR

We take the time for you

Contact us at any time

CONTACT FORM PATIENT

We take the time for you

Sie fragen, wir antworten

Haben Sie Fragen? Hier finden Sie ANtworten!

Was ist die Testung genetischer Expressionswerte von Krebszellen?

Durch molekularbiologische Analyse identifizieren wir das individuelle Aktionsprofil eines Tumors und finden die therapeutischen Angriffspunkte.

Die Messung der RNA-Genexpressionswerte ist dem Tumorgeschehen näher als eine reine Mutationsanalyse. Mit dieser Messung kann man für wichtige Signalwege des Tumors das konkrete und aktuelle Aktionsprofil und deren Eigenschaften ermitteln.

Per Flüssigbiopsie ist eine Gewinnung frischer lebender Tumorzellen einfach und schmerzfrei möglich.  

Es werden auch Tumorzellen aus Körperregionen gewonnen, die wie in Lunge, Bauchspeicheldrüsen oder Gehirn für herkömmliche Gewebebiopsien oft nur schwierig zu erreichen sind.

Man kann weiterhin auch Tumorzellen aus Urin, Aszites oder Liquor erhalten.

Wenn Gewebebiopsate vorliegen, kann man auch diese nutzen. Somit sind vielfältige Möglichkeiten gegeben, um Tumorzellen zu gewinnen.

Die iSelect und iComplete Tests liefern entscheidende Erkenntnisse bezüglich:

• der Aggressivität des Tumors

• der Manipulation des Immunsystems durch den Tumor

• der Resistenzen gegenüber Medikamenten

• der Aktivität relevanter Signale

• der Wirksamkeit bestimmter Substanzen

Die Messergebnisse werden therapeutischen Substanzen zugeordnet, basierend auf anerkannten Studien, sodass der behandelnde Arzt Optionen für eine gezielte Therapie erhält.

Üblicherweise werden die Tumorzellen aus einer Blutprobe extrahiert, gefolgt von der Analyse der RNA, um die Aktivität von Genen zu bestimmen. Die Tumorzellen können aber auch aus einer Biopsie, Liquor oder Aszites entnommen werden.

Die mit dem iSelect oder iComplete Test gewonnen Therapieoptionen zeigen personalisierte und für den individuellen Tumor zielgerichtete Therapieoptionen auf, die der Therapeut umsetzen kann. Weiterhin werden auch individuell für den vorliegenden Tumor ungeeignete Substanzen die z.B. in der Chemotherapie eingesetzt werden, aufgezeigt. Damit kann man z.B. stark toxische Therapeutika, die der Tumor einfach durchschleust, identifizieren und für die Therapie ausschließen.

Bitte sprechen Sie uns über die kostenlose Beratung an, damit wir den richtigen Test herausfinden und Ihnen die damit verbundenen Kosten mitteilen können.

Die Laborarbeit dauert ca. 10 Arbeitstage. Danach wird ein Bericht geschrieben, der je nach Komplexität des Falles ca. 1 – 3 Arbeitstage dauern kann. Der Bericht muss wegen gesetzlicher Vorgaben im Falle von Krebs an den behandelnden Arzt gehen. Er kann dann den Bericht an den Patienten weiterleiten.

1

Kontaktieren Sie uns und bestellen Sie das Blutabnahmeset für Ihren Arzt

Rufen Sie bei uns an oder schicken Sie uns eine Nachricht. Wir beraten Sie zu unseren Tests. Das entsprechende Blutentnahmeset lassen wir Ihrem Arzt kostenlos zukommen.

2

Vereinbaren Sie einen Termin zur Blutabnahme bei Ihrem Arzt

Die Blutabnahme erfolgt bei dem Arzt Ihres Vertrauens oder einem Arzt unseres Netzwerkes. Wichtig für Chemotherapie-Patienten: Planen Sie diesen Termin frühestens 10-14 Tage nach Ihrer letzten Chemotherapie.

3

Ihr Arzt oder Sie:
Informieren Sie uns über Ihren Blutabnahmetermin

Teilen Sie uns spätestens einen Tag vor der geplanten Blutabnahme per E-Mail oder telefonisch mit, wann und wo die Probe abgeholt werden soll. Wir benötigen Ort, Datum und ein Zeitfenster von 2 Stunden für unseren Kurierdienst.

Nur so können wir die Abholung der Probe in Ihrer Praxis organisieren.

4

Nehmen Sie das Blutabnahmeset zum Arzttermin mit

Bringen Sie das von uns erhaltene Blutabnahmeset zu Ihrem Arzttermin mit. Nach der Blutabnahme wird die Probe durch unseren Kurierdienst abgeholt und zu unserem Labor transportiert.

5

LASSEN SIE DURCH IHREN ARZT DIE UNTERLAGEN AUSFÜLLEN, UNTERSCHREIBEN SIE DEN AUFTRAG und senden Sie sie zurück

  • Prüfen Sie die Vollständigkeit der beiliegenden Unterlagen
  • Lassen Sie den Arzt den Auftrag zur molekularen Diagnostik mit Ihrer Einwilligung und Unterschrift ausfüllen
  • Ergänzen Sie den beiliegenden Medikamentenplan
  • Legen Sie Kopien Ihrer Klinik-Berichte/Anamnesen bei
  • Senden Sie alle Formulare unterschrieben im Original an uns zurück

6

Besprechen Sie die Ergebnisse mit Ihrem Arzt

Die Berichterstellung erfolgt nach Zahlungseingang des Patienten je nach Fall innerhalb von ca. 10-15 Werktagen.

Vereinbaren Sie einen Beratungstermin mit Ihrem Arzt zur Besprechung der Testergebnisse. Wir senden  den Testbericht direkt an Ihren Arzt.

Kontaktieren Sie uns zu jeder Zeit

Wir nehmen uns die zeit für Sie

We wish you a pleasant journey

Contact us at any time

CONTACT FORM DOCTOR

We take the time for you

Contact us at any time

CONTACT FORM PATIENT

We take the time for you

tumor diagnostics cancer

iPREVENT

The blood test for early detection or monitoring of cancer

Tumors release cancer cells into the blood (circulating tumor cells – CTC) at a very early stage. If these cells settle elsewhere in the body, they develop into metastases. iPREVENT often detects circulating tumor cells in the blood at a very early stage, when imaging methods (ultrasound, CT, MRI) do not yet show anything.

If a large number of such cells are found, the iSelect or iComplete test can be connected.
This means that tumors can usually be detected at an early stage and treated appropriately. Early treatment usually significantly increases success and the chances of survival. The gentler treatment options in the early stages also mean that significantly fewer side effects can be expected.

THE iPREVENT TEST OFFERS DECISIVE ADVANTAGES:

Contact us at any time

WE ADVISE YOU FREE OF CHARGE!

CONTACT FORM PATIENT

We take the time for you

cancer diagnostics

iSELECT

Comprehensive personalized tumor diagnostics for complementary therapeutics

The iSELECT test evaluates tumor cells for the expression of 35 genes. Gene expression profiles describe the extent to which a gene is active and, consequently, the signaling and metabolic pathways within the tumor cell that depend on it. The test focuses on genes that are particularly important for tumor growth and that characterize the cancer. The advantage of the test is that the analysis of these characteristics generates a personalized activity profile of the tumor.

By comparing the data with scientific studies, potential complementary substances (plant-based substances and off-label medications) are identified and compiled for medical evaluation. The results are tailored to the specific stage of the disease and are intended to serve as the basis for a complementary treatment approach that is as gentle as possible. They are presented in an easy-to-understand, detailed report.

As the disease progresses, the test is used during and after cancer treatment to identify changes in signaling and metabolic pathways that may indicate a recurrence. Treatment can then be adjusted accordingly.

THE iSELECT TEST PROVIDES INFORMATION ON:

You will receive a detailed report containing the analysis results and references that your medical team can take into account when planning your treatment.

Important: The interpretation of the results and all treatment decisions are made exclusively by your treating physicians.

Contact us at any time

WE ADVISE YOU FREE OF CHARGE!

PATIENT CONTACT FORM

We take the time for you

Liquid Biopsy for cancer

iCOMPLETE

LABORATORY DIAGNOSTIC TEST FOR THE MOLECULAR ANALYSIS OF GENE EXPRESSION PATTERNS IN TUMOR DISEASES

The iCOMPLETE test analyzes a panel of 85+ gene expressions. The test focuses on genes associated with tumor growth and tumor characteristics.

The iCOMPLETE test identifies molecular activity patterns regardless of tumor type and provides information on potential treatment approaches to serve as a basis for clinical treatment decisions. The analysis can help treating physicians select personalized treatment options based on each patient’s individual profile.

The iCOMPLETE test analyzes gene expression profiles from the patient’s blood. Gene expression provides information about the extent to which a gene is active and which signaling and metabolic pathways in the tumor cell may be associated with it.

Based on scientific studies, the iCOMPLETE test identifies approved medications—including chemotherapy drugs, targeted therapies, and immunotherapies—as well as natural substances or off-label medications associated with the signaling or metabolic pathways under investigation. The results are presented in a structured laboratory report.

Throughout the course of the disease, testing during and after cancer treatment can provide information about changes in signaling and metabolic pathways. This molecular information can help the treating physician adjust the treatment plan.

IMPORTANT INFORMATION ON TEST INTERPRETATION:

This test provides molecular biological information about your tumor. It does not constitute a treatment recommendation. The substances mentioned in the report are based on scientific publications and should be understood as potential points of consideration for medical evaluation.

The selection, prescription, and dosage of all medications and substances—including herbal active ingredients—are determined exclusively by your treating physician, taking into account your overall medical condition.

The effectiveness of the substances mentioned cannot be guaranteed in individual cases. Off-label medications and herbal supplements can also cause side effects and interactions.

Note on Off-Label Medications: The use of medications outside their approved indications (off-label use) is at your doctor’s discretion and at your own risk. No standard clinical trials have been conducted for these uses.

THE iCOMPLETE TEST PROVIDES INFORMATION ON:

The laboratory report presents research-based information on conventional and complementary treatment approaches that are related to the identified molecular patterns based on gene expression analysis. This information serves as a basis for treating physicians to make individualized treatment decisions.

Important: The interpretation of the results and all treatment decisions are made exclusively by your treating physicians.

Contact us at any time

WE ADVISE YOU FREE OF CHARGE!

PATIENT CONTACT FORM

We take the time for you

tumor diagnostics cancer

iPREVENT

The blood test for early detection or monitoring of cancer

Tumors release cancer cells into the blood (circulating tumor cells – CTC) at a very early stage. If these cells settle elsewhere in the body, they develop into metastases. iPREVENT often detects circulating tumor cells in the blood at a very early stage, when imaging methods (ultrasound, CT, MRI) do not yet show anything.

If a large number of such cells are found, the iSelect or iComplete test can be connected.
This means that tumors can usually be detected at an early stage and treated appropriately. Early treatment usually significantly increases success and the chances of survival. The gentler treatment options in the early stages also mean that significantly fewer side effects can be expected.

THE iPREVENT TEST OFFERS DECISIVE ADVANTAGES:

Contact us at any time

WE ADVISE YOU FREE OF CHARGE!

CONTACT FORM PATIENT

We take the time for you

cancer diagnostics

iSELECT

Comprehensive personalized tumor diagnostics for complementary therapeutics

The iSELECT test evaluates tumor cells for the expression of 35 genes. Gene expression profiles describe the extent to which a gene is active and, consequently, the signaling and metabolic pathways within the tumor cell that depend on it. The test focuses on genes that are particularly important for tumor growth and that characterize the cancer. The advantage of the test is that the analysis of these characteristics generates a personalized activity profile of the tumor.

By comparing the data with scientific studies, potential complementary substances (plant-based substances and off-label medications) are identified and compiled for medical evaluation. The results are tailored to the specific stage of the disease and are intended to serve as the basis for a complementary treatment approach that is as gentle as possible. They are presented in an easy-to-understand, detailed report.

As the disease progresses, the test is used during and after cancer treatment to identify changes in signaling and metabolic pathways that may indicate a recurrence. Treatment can then be adjusted accordingly.

THE iSELECT TEST PROVIDES INFORMATION ON:

You will receive a detailed report containing the analysis results and references that your medical team can take into account when planning your treatment.

Important: The interpretation of the results and all treatment decisions are made exclusively by your treating physicians.

Contact us at any time

WE ADVISE YOU FREE OF CHARGE!

PATIENT CONTACT FORM

We take the time for you

Liquid Biopsy for cancer

iCOMPLETE

LABORATORY DIAGNOSTIC TEST FOR THE MOLECULAR ANALYSIS OF GENE EXPRESSION PATTERNS IN TUMOR DISEASES

The iCOMPLETE test analyzes a panel of 85+ gene expressions. The test focuses on genes associated with tumor growth and tumor characteristics.

The iCOMPLETE test identifies molecular activity patterns regardless of tumor type and provides information on potential treatment approaches to serve as a basis for clinical treatment decisions. The analysis can help treating physicians select personalized treatment options based on each patient’s individual profile.

The iCOMPLETE test analyzes gene expression profiles from the patient’s blood. Gene expression provides information about the extent to which a gene is active and which signaling and metabolic pathways in the tumor cell may be associated with it.

Based on scientific studies, the iCOMPLETE test identifies approved medications—including chemotherapy drugs, targeted therapies, and immunotherapies—as well as natural substances or off-label medications associated with the signaling or metabolic pathways under investigation. The results are presented in a structured laboratory report.

Throughout the course of the disease, testing during and after cancer treatment can provide information about changes in signaling and metabolic pathways. This molecular information can help the treating physician adjust the treatment plan.

IMPORTANT INFORMATION ON TEST INTERPRETATION:

This test provides molecular biological information about your tumor. It does not constitute a treatment recommendation. The substances mentioned in the report are based on scientific publications and should be understood as potential points of consideration for medical evaluation.

The selection, prescription, and dosage of all medications and substances—including herbal active ingredients—are determined exclusively by your treating physician, taking into account your overall medical condition.

The effectiveness of the substances mentioned cannot be guaranteed in individual cases. Off-label medications and herbal supplements can also cause side effects and interactions.

Note on Off-Label Medications: The use of medications outside their approved indications (off-label use) is at your doctor’s discretion and at your own risk. No standard clinical trials have been conducted for these uses.

THE iCOMPLETE TEST PROVIDES INFORMATION ON:

The laboratory report presents research-based information on conventional and complementary treatment approaches that are related to the identified molecular patterns based on gene expression analysis. This information serves as a basis for treating physicians to make individualized treatment decisions.

Important: The interpretation of the results and all treatment decisions are made exclusively by your treating physicians.

Contact us at any time

WE ADVISE YOU FREE OF CHARGE!

PATIENT CONTACT FORM

We take the time for you

We wish you a pleasant journey